US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PMGC Holdings

2.01

-0.0700-3.37%

Volume:545.16K

Turnover:1.09M

Market Cap:2.76M

PE:-0.03

High:2.08

Open:2.05

Low:1.95

Close:2.08

Loading ...

Overview Company News Filings

PMGC Holdings Inc. Announces Intent to Acquire Established California CNC Machining Company

Pmgc Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based as9100d & Iso 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for Over 35 Years

THOMSON REUTERS

PMGC Holdings Signs LOI for U.S. Electronics Acquisition

PMGC Holdings Inc. Signs Letter of Intent to Acquire U.S.-Based Electronics Manufacturing Company

Pmgc Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company

THOMSON REUTERS

Northstrive Biosciences Announces Completion of Phase I Strategic Review for El-22 Targeting Muscle Loss Associated With Glp-1 Weight Loss Drugs and Age-Related Sarcopenia

THOMSON REUTERS

Northstrive Biosciences Amends License Agreement with MOA Life

Northstrive Biosciences Secures Exclusive EL-22 Animal Health Licensing Deal with Modulant Biosciences

PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics

ELEVAI Labs Inc. Enters New Secondment Agreement

PMGC Holdings Inc. Enters into Secondment Agreement with Northstrive Companies Inc

Northstrive Biosciences, a Subsidiary of PMGC Holdings, Signs Term Sheet with Modulant for EL-22 Animal Health Licensing

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial

BRIEF-PMGC Holdings Enters Sales Agreement With Univest Securities

BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment

Northstrive Biosciences Announces Positive FDA Response Supporting a Submission of Ind for a Phase 2 Clinical Trial for El-22 in Combination With Glp-1 Receptor Agonist for Obesity Treatment

THOMSON REUTERS

Pmgc Holdings Inc - Northstrive to File Ind Application in 2025

THOMSON REUTERS

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

Pmgc Holdings Inc - Enters Sales Agreement With Univest Securities - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ELAB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELAB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELAB\",,,,,undefined,":{"symbol":"ELAB","market":"US","secType":"STK","nameCN":"PMGC Holdings","latestPrice":2.01,"timestamp":1750086328608,"preClose":2.08,"halted":0,"volume":545158,"delay":0,"floatShares":707099,"shares":1375385,"eps":-78.48178,"marketStatus":"Trading","change":-0.07,"latestTime":"06-16 11:06:41 EDT","open":2.05,"high":2.08,"low":1.95,"amount":1090387.960856,"amplitude":0.0625,"askPrice":2.08,"askSize":2488,"bidPrice":2,"bidSize":60,"shortable":3,"etf":0,"ttmEps":-78.48178,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750104000000},"marketStatusCode":2,"adr":0,"listingDate":1700542800000,"exchange":"NASDAQ","adjPreClose":2.08,"preHourTrading":{"tag":"盘前","latestPrice":2.03,"preClose":2.08,"latestTime":"09:29 EDT","volume":241693,"amount":537731.4686369,"timestamp":1750080544311},"postHourTrading":{"tag":"盘后","latestPrice":2.06,"preClose":2.08,"latestTime":"19:45 EDT","volume":1814,"amount":3762.5011,"timestamp":1749858316163},"volumeRatio":0.37987},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELAB\",,,,,undefined,":{"symbol":"ELAB","floatShares":707099,"roa":"-36.92%","roe":"-95.21%","lyrEps":-78.481779,"volumeRatio":0.37987,"shares":1375385,"dividePrice":0,"high":2.08,"amplitude":0.0625,"preClose":2.08,"low":1.95,"week52Low":1.945,"pbRate":"0.34","psRate":"1.13","week52High":896,"institutionHeld":0,"latestPrice":2.01,"committee":-0.952904,"eps":-78.48178,"divideRate":0,"volume":545158,"delay":0,"ttmEps":-78.48178,"open":2.05,"prevYearClose":16.03,"prevWeekClose":2.08,"prevMonthClose":2.09,"prevQuarterClose":4.63,"fiveDayClose":2.64,"twentyDayClose":2.47,"sixtyDayClose":6.4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELAB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2543672830","title":"PMGC Holdings Inc. Announces Intent to Acquire Established California CNC Machining Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2543672830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543672830?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:00","pubTimestamp":1750075218,"startTime":"0","endTime":"0","summary":"NEWPORT BEACH, Calif., June 16, 2025 - PMGC Holdings Inc.  announced the signing of a non-binding Letter of Intent to acquire a California-based CNC machining company with over 35 years of operational history. This acquisition target is AS9100D and ISO 9001:2015 certified, specializing in precision milling, turning, mold manufacturing, and specialty metals expertise for the aerospace, defense, and industrial markets. This marks PMGC's third pending acquisition since April 2025, highlighting its active mergers and acquisitions strategy with more deals anticipated this year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 16, 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL5Skx7N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4588","LU2210149790.SGD","LU2095319765.USD","NDAQ","BK4585","IE00B3QW5Z07.USD","ELAB"],"gpt_icon":0},{"id":"2543674750","title":"Pmgc Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based as9100d & Iso 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for Over 35 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2543674750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543674750?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:00","pubTimestamp":1750075208,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nFWN3SJ09A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2542334219","title":"PMGC Holdings Signs LOI for U.S. Electronics Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2542334219","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542334219?lang=en_us&edition=fundamental","pubTime":"2025-06-10 02:27","pubTimestamp":1749493674,"startTime":"0","endTime":"0","summary":"ELEVAI Labs Inc. ( ($ELAB) ) has provided an update. On June 9, 2025, PMGC Holdings Inc. announced the signing of a non-binding Letter of Intent to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pmgc-holdings-signs-loi-for-u-s-electronics-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pmgc-holdings-signs-loi-for-u-s-electronics-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2542381015","title":"PMGC Holdings Inc. Signs Letter of Intent to Acquire U.S.-Based Electronics Manufacturing Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2542381015","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542381015?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:00","pubTimestamp":1749470425,"startTime":"0","endTime":"0","summary":"PMGC Holdings Inc., a diversified public holding company, has announced the signing of a non-binding Letter of Intent to acquire a U.S.-based electronics contract manufacturing company. The target company specializes in high-precision electrical and mechanical assembly, including printed circuit board manufacturing, and has over 40 years of operational history. This acquisition marks PMGC's second pending acquisition since April, as part of its ongoing M&A strategy, with more deals expected later this year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDLbfcJ4C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NDAQ","BK4588","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","ELAB","LU2210149790.SGD","BK4112","BK4183","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2542381452","title":"Pmgc Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2542381452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542381452?lang=en_us&edition=fundamental","pubTime":"2025-06-09 20:00","pubTimestamp":1749470400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nTUA48D5J4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2537946582","title":"Northstrive Biosciences Announces Completion of Phase I Strategic Review for El-22 Targeting Muscle Loss Associated With Glp-1 Weight Loss Drugs and Age-Related Sarcopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2537946582","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537946582?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:16","pubTimestamp":1747916193,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUABK0NDN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2536342989","title":"Northstrive Biosciences Amends License Agreement with MOA Life","url":"https://stock-news.laohu8.com/highlight/detail?id=2536342989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536342989?lang=en_us&edition=fundamental","pubTime":"2025-05-17 03:17","pubTimestamp":1747423046,"startTime":"0","endTime":"0","summary":"ELEVAI Labs Inc. ( ($ELAB) ) has issued an announcement. On May 12, 2025, Northstrive Biosciences Inc. entered into a Second Amendment to its Licen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/northstrive-biosciences-amends-license-agreement-with-moa-life?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/northstrive-biosciences-amends-license-agreement-with-moa-life?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2536974344","title":"Northstrive Biosciences Secures Exclusive EL-22 Animal Health Licensing Deal with Modulant Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2536974344","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536974344?lang=en_us&edition=fundamental","pubTime":"2025-05-17 02:58","pubTimestamp":1747421929,"startTime":"0","endTime":"0","summary":"Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced the signing of a binding term sheet with Modulant Biosciences LLC. This agreement outlines the terms for a future definitive licensing arrangement, granting Modulant exclusive global rights to develop and commercialize EL-22 for animal health applications. This collaboration marks a strategic opportunity for Northstrive to monetize the intellectual property of EL-22, potentially transforming it into a long-term revenue-generating asset. The license allows Modulant to utilize EL-22 in various animal health applications, including as a feed additive, with the exception of the Republic of Korea. Modulant, led by seasoned biotechnology executive Tom Campi, will also have the right to sublicense the technology globally. Financial terms include revenue sharing, where Northstrive will receive a percentage of revenues until a specified limit, after which the royalty rate will decrease. The parties aim to finalize t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL7fqjbC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2535302543","title":"PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2535302543","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535302543?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:00","pubTimestamp":1747224057,"startTime":"0","endTime":"0","summary":"PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. , has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. . This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL3Z3jdl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4112","BK4588","IE00B3QW5Z07.USD","BK4139","ELAB","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","BK4183","TCRT","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2535033937","title":"ELEVAI Labs Inc. Enters New Secondment Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2535033937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535033937?lang=en_us&edition=fundamental","pubTime":"2025-05-14 05:16","pubTimestamp":1747171000,"startTime":"0","endTime":"0","summary":"ELEVAI Labs Inc. ( ($ELAB) ) just unveiled an announcement. On May 7, 2025, PMGC Holdings Inc. entered into a Secondment Agreement with Northstrive...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/elevai-labs-inc-enters-new-secondment-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/elevai-labs-inc-enters-new-secondment-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2535817080","title":"PMGC Holdings Inc. Enters into Secondment Agreement with Northstrive Companies Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2535817080","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535817080?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:51","pubTimestamp":1747169499,"startTime":"0","endTime":"0","summary":"PMGC Holdings Inc. has announced a new contractual agreement with Northstrive Companies Inc., a California-based corporation. The agreement, effective as of May 7, 2025, involves Northstrive seconding certain employees to PMGC Holdings to provide specified services. These employees will remain on Northstrive's payroll while delivering services to PMGC Holdings. The agreement outlines details regarding employee responsibilities, location of service provision, and termination procedures. It also includes standard provisions related to confidentiality and liability. This strategic collaboration aims to enhance operational efficiency and service delivery for PMGC Holdings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDLw06YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2535727969","title":"Northstrive Biosciences, a Subsidiary of PMGC Holdings, Signs Term Sheet with Modulant for EL-22 Animal Health Licensing","url":"https://stock-news.laohu8.com/highlight/detail?id=2535727969","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535727969?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:00","pubTimestamp":1747137635,"startTime":"0","endTime":"0","summary":"Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced a significant collaboration with Modulant Biosciences LLC. The two companies have signed a binding term sheet that grants Modulant exclusive global rights to develop and commercialize EL-22, a pioneering probiotic approach aimed at muscle preservation in livestock. This strategic partnership allows Northstrive to monetize its intellectual property in the animal health sector. If successfully developed and brought to market, EL-22 could become a long-term revenue-generating asset. The agreement also outlines that Modulant will share a portion of revenues from sublicensing and commercial activities with Northstrive, with specified royalty rates. The parties plan to finalize the definitive licensing agreement in the coming months, pending necessary approvals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL3pwy1g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4183","BK4588","NDAQ","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","BK4585","ELAB","LU2210150020.SGD"],"gpt_icon":0},{"id":"2531173250","title":"Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2531173250","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531173250?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"NEWPORT BEACH, Calif., April 29, 2025  -- Northstrive Biosciences Inc. , a subsidiary of PMGC Holdings Inc.  , today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists.The Company filed the following four patents today:. EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals .EL-32 in Obesity as Monotherapy and Combination with GLP-1: Updated patent filings for Pharmaceutical Composition for Treatment of Muscle Loss Due to Obesity Treatments , and Combination Therapy for Treatment of Muscle Loss Due to Obesity Treatments utilizing GLP-1 receptor agonists .“We believe that EL-22 and EL-32 have the potential to treat obesity in combination with GLP-1 receptor agonists, while also serving as the foundation to a potential range of ani","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northstrive-biosciences-strengthens-ip-portfolio-120000070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0690374615.EUR","LU1481599808.USD","LU2404859667.USD","EL","LU2404859741.USD","BK4585","ELAB","LU1487256676.USD","BK4533","BK4504","BK4588","LU0690374961.EUR","LU1169590202.USD","VAQC","BK4183","LU1481600234.SGD","LU1169589451.USD","LU2552382058.USD","BK4548","BK4136","BK4558","IP","LU2552382132.HKD","IE00B3T34201.USD","LU2463526074.USD","LU2552382215.SGD","BK4561"],"gpt_icon":0},{"id":"2530440591","title":"Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530440591","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530440591?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"NEWPORT BEACH, Calif., April 28, 2025  -- Northstrive Biosciences Inc. , a subsidiary of PMGC Holdings Inc.  , is proud to announce that Co-Founder Deniel Mero was recently featured in an exclusive interview hosted by Bear Bull Traders, a leading global online stock trading community for professional and aspiring traders.During the interview, Mr. Mero discussed Northstrive’s recent milestone: receiving preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists. EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.Bear Bull Traders is an international trading education community founded in 2015 by Andrew Aziz. With over 100,000 members globally, Bear Bull Traders offers comprehensive education, expert mentorship, and community supp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northstrive-biosciences-co-founder-featured-120000019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2404859741.USD","LU2552382132.HKD","EL","BK4558","BK4504","BK4585","LU2404859667.USD","BK4183","LU0690374961.EUR","LU2552382215.SGD","BK4588","ELAB","LU2552382058.USD","LU0690374615.EUR","BK4533","BK4548"],"gpt_icon":0},{"id":"2529592987","title":"BRIEF-PMGC Holdings Enters Sales Agreement With Univest Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2529592987","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529592987?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:57","pubTimestamp":1745499476,"startTime":"0","endTime":"0","summary":"BRIEF-PMGC Holdings Enters Sales Agreement With Univest SecuritiesApril 24  - PMGC Holdings Inc ELAB.O:PMGC HOLDINGS INC - ENTERS SALES AGREEMENT WITH UNIVEST SECURITIES - SEC FILINGPMGC HOLDINGS INC - TO ISSUE AND SELL UP TO $100 MILLION IN COMMON STOCK - SEC FILINGFurther company coverage: ELAB.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R225T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAB"],"gpt_icon":0},{"id":"2529166989","title":"BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529166989","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529166989?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:18","pubTimestamp":1745497096,"startTime":"0","endTime":"0","summary":"BRIEF-Northstrive Biosciences Announces Positive FDA Response Supporting A Submission Of IND For A Phase 2 Clinical Trial For EL-22 In Combination With GLP-1 Receptor Agonist For Obesity TreatmentApri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA5MCKTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2529986363","title":"Northstrive Biosciences Announces Positive FDA Response Supporting a Submission of Ind for a Phase 2 Clinical Trial for El-22 in Combination With Glp-1 Receptor Agonist for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529986363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529986363?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496057,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA5MCKTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0},{"id":"2529868269","title":"Pmgc Holdings Inc - Northstrive to File Ind Application in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529868269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529868269?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496057,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA5MCKTP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELAB","BK4183"],"gpt_icon":0},{"id":"2529354269","title":"Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529354269","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529354269?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:00","pubTimestamp":1745496000,"startTime":"0","endTime":"0","summary":"Northstrive Biosciences received preliminary meeting responses from the FDA regarding Northstrive’s nonclinical studies and clinical development plans for EL-22, administered in combination with GLP-1 receptor agonists.Northstrive believes the FDA responses encourage a path forward for filing an IND application to conduct a Phase 2 clinical trial in overweight or obese patients.EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.NEWPORT BEACH, Calif., April 24, 2025  -- Northstrive Biosciences Inc. , a subsidiary of PMGC Holdings Inc.  , announced that it has received preliminary responses and commentary from the U.S. Food and Drug Administration  regarding its scheduled Type B pre-Investigational New Drug  meeting. Northstrive initially requested this meeting with the FDA to discuss nonclinical studies and Northstrive Biosciences’ clinical development p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/northstrive-biosciences-announces-positive-fda-120000281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ELAB","BK4590","LU2552382058.USD","EL","LU0690374961.EUR","LU2552382132.HKD","BK4585","LU0690374615.EUR","BK4548","BK4533","BK4144","LU2552382215.SGD","BK4588","BK4558","BK4504","LU2404859741.USD","LU2404859667.USD","BK4183","GLP"],"gpt_icon":0},{"id":"2529605494","title":"Pmgc Holdings Inc - Enters Sales Agreement With Univest Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529605494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529605494?lang=en_us&edition=fundamental","pubTime":"2025-04-24 18:19","pubTimestamp":1745489962,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R225T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ELAB"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELAB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-10","symbol":"ELAB","defaultRemindTime":1741613400000,"type":"split","dateTimestamp":1741579200000,"forFactor":7,"toFactor":1,"ratio":7},{"market":"US","date":"2024-11-27","symbol":"ELAB","defaultRemindTime":1732717800000,"type":"split","dateTimestamp":1732683600000,"forFactor":200,"toFactor":1,"ratio":200}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELAB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELAB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELAB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELAB","date":"2025-06-13","current":-0.462229,"percent":0.837398,"low":-19.933298,"twenty":-3.158012,"median":-1.322196,"eighty":-0.515702,"high":-0.185003,"avg":-2.426643,"sd":3.10767,"marketCap":2984585},"quantilePoints":[{"date":"2023-11-24","current":-18.255744,"twenty":-17.959705,"median":-17.515646,"eighty":-17.071587,"marketCap":64119575},{"date":"2023-12-01","current":-13.864497,"twenty":-19.360956,"median":-18.255744,"eighty":-16.918634,"marketCap":48696218},{"date":"2023-12-08","current":-10.509387,"twenty":-18.255744,"median":-15.443372,"eighty":-11.703412,"marketCap":36912079},{"date":"2023-12-15","current":-8.308155,"twenty":-18.10279,"median":-11.940243,"eighty":-9.335099,"marketCap":31539899},{"date":"2023-12-22","current":-8.354717,"twenty":-17.34789,"median":-10.682077,"eighty":-8.450306,"marketCap":31716661},{"date":"2023-12-29","current":-8.216856,"twenty":-16.918634,"median":-10.164008,"eighty":-8.299025,"marketCap":31193307},{"date":"2024-01-05","current":-7.303872,"twenty":-15.709807,"median":-9.153506,"eighty":-8.280766,"marketCap":27727384},{"date":"2024-01-12","current":-8.125558,"twenty":-14.012516,"median":-8.832664,"eighty":-8.070779,"marketCap":30846714},{"date":"2024-01-19","current":-4.884465,"twenty":-13.479646,"median":-8.376629,"eighty":-7.906442,"marketCap":18542688},{"date":"2024-01-26","current":-3.42369,"twenty":-11.881035,"median":-8.330979,"eighty":-7.359564,"marketCap":12997211},{"date":"2024-02-02","current":-3.834533,"twenty":-11.486317,"median":-8.216856,"eighty":-4.738387,"marketCap":14556876},{"date":"2024-02-09","current":-2.921549,"twenty":-10.785691,"median":-8.079909,"eighty":-3.801666,"marketCap":11090953},{"date":"2024-02-16","current":-3.323718,"twenty":-10.440311,"median":-7.942961,"eighty":-3.414564,"marketCap":12617692},{"date":"2024-02-23","current":-3.218269,"twenty":-10.164008,"median":-7.897312,"eighty":-3.378041,"marketCap":12217378},{"date":"2024-03-01","current":-3.181749,"twenty":-9.179141,"median":-7.443102,"eighty":-3.218269,"marketCap":12078741},{"date":"2024-03-08","current":-3.378041,"twenty":-9.127872,"median":-4.975763,"eighty":-3.263918,"marketCap":12823915},{"date":"2024-03-15","current":-3.555616,"twenty":-8.855945,"median":-4.679044,"eighty":-3.323718,"marketCap":13498037},{"date":"2024-03-22","current":-3.491707,"twenty":-8.832664,"median":-3.834533,"eighty":-3.332848,"marketCap":13255422},{"date":"2024-03-28","current":-3.149795,"twenty":-8.668692,"median":-3.638241,"eighty":-3.254788,"marketCap":11957434},{"date":"2024-04-05","current":-2.739531,"twenty":-8.426843,"median":-3.539867,"eighty":-3.191975,"marketCap":11784138},{"date":"2024-04-12","current":-2.578785,"twenty":-8.359099,"median":-3.514988,"eighty":-3.15016,"marketCap":11092686},{"date":"2024-04-19","current":-2.356802,"twenty":-8.353987,"median":-3.494218,"eighty":-3.138017,"marketCap":10137824},{"date":"2024-04-26","current":-2.715358,"twenty":-8.317285,"median":-3.457927,"eighty":-2.966103,"marketCap":11680160},{"date":"2024-05-03","current":-2.840249,"twenty":-8.271636,"median":-3.430537,"eighty":-2.908834,"marketCap":12217378},{"date":"2024-05-10","current":-2.751214,"twenty":-8.225986,"median":-3.400866,"eighty":-2.810275,"marketCap":11834394},{"date":"2024-05-17","current":-2.439543,"twenty":-8.198597,"median":-3.378041,"eighty":-2.734696,"marketCap":11265982},{"date":"2024-05-24","current":-2.476318,"twenty":-8.139253,"median":-3.346086,"eighty":-2.649774,"marketCap":11435812},{"date":"2024-05-31","current":-2.456058,"twenty":-8.070779,"median":-3.333761,"eighty":-2.615446,"marketCap":11342250},{"date":"2024-06-07","current":-2.620224,"twenty":-8.03426,"median":-3.293818,"eighty":-2.590871,"marketCap":12100380},{"date":"2024-06-14","current":-2.536364,"twenty":-7.99774,"median":-3.211422,"eighty":-2.574044,"marketCap":11713111},{"date":"2024-06-21","current":-2.409546,"twenty":-7.933831,"median":-3.194759,"eighty":-2.543297,"marketCap":11127455},{"date":"2024-06-28","current":-2.408319,"twenty":-7.915572,"median":-3.18814,"eighty":-2.539819,"marketCap":11121788},{"date":"2024-07-05","current":-2.340001,"twenty":-7.897312,"median":-3.163489,"eighty":-2.517446,"marketCap":10806289},{"date":"2024-07-12","current":-2.148137,"twenty":-7.860792,"median":-3.149795,"eighty":-2.484198,"marketCap":9920249},{"date":"2024-07-15","current":-2.063455,"twenty":-7.842533,"median":-3.149795,"eighty":-2.476543,"marketCap":9529182},{"date":"2024-08-02","current":-1.8,"twenty":-7.824273,"median":-3.149795,"eighty":-2.472639,"marketCap":8312530},{"date":"2024-08-09","current":-1.490993,"twenty":-7.627068,"median":-3.134046,"eighty":-2.438304,"marketCap":6885510},{"date":"2024-08-16","current":-1.275527,"twenty":-7.359564,"median":-3.024259,"eighty":-2.416511,"marketCap":6059653},{"date":"2024-08-23","current":-0.996722,"twenty":-6.536966,"median":-2.921549,"eighty":-2.408074,"marketCap":4735130},{"date":"2024-08-30","current":-1.174958,"twenty":-5.249658,"median":-2.921549,"eighty":-2.362653,"marketCap":5581877},{"date":"2024-09-06","current":-1.375091,"twenty":-4.920984,"median":-2.840249,"eighty":-2.345852,"marketCap":6532648},{"date":"2024-09-13","current":-1.357574,"twenty":-4.774907,"median":-2.7913,"eighty":-2.312486,"marketCap":6449430},{"date":"2024-09-20","current":-1.33918,"twenty":-4.674479,"median":-2.751214,"eighty":-2.26391,"marketCap":6362050},{"date":"2024-09-27","current":-0.556488,"twenty":-4.272766,"median":-2.706294,"eighty":-1.721618,"marketCap":2643710},{"date":"2024-10-04","current":-0.825353,"twenty":-3.907572,"median":-2.663183,"eighty":-1.516044,"marketCap":3921009},{"date":"2024-10-11","current":-0.609011,"twenty":-3.809883,"median":-2.623475,"eighty":-1.448755,"marketCap":2893229},{"date":"2024-10-18","current":-0.543983,"twenty":-3.700324,"median":-2.618669,"eighty":-1.401366,"marketCap":2584301},{"date":"2024-10-25","current":-0.958273,"twenty":-3.624547,"median":-2.598328,"eighty":-1.356698,"marketCap":4552470},{"date":"2024-10-31","current":-0.965548,"twenty":-3.591497,"median":-2.58341,"eighty":-1.330061,"marketCap":4587034},{"date":"2024-11-08","current":-0.186042,"twenty":-3.543017,"median":-2.570883,"eighty":-1.290658,"marketCap":883831},{"date":"2024-11-15","current":-0.272307,"twenty":-3.520466,"median":-2.545057,"eighty":-1.259215,"marketCap":1293652},{"date":"2024-11-22","current":-1.912035,"twenty":-3.514988,"median":-2.532982,"eighty":-1.195453,"marketCap":10456757},{"date":"2024-11-29","current":-0.970216,"twenty":-3.514075,"median":-2.507089,"eighty":-1.176604,"marketCap":5306027},{"date":"2024-12-06","current":-0.979681,"twenty":-3.507684,"median":-2.495456,"eighty":-1.057426,"marketCap":5357793},{"date":"2024-12-13","current":-1.055406,"twenty":-3.495725,"median":-2.476318,"eighty":-1.052022,"marketCap":5771922},{"date":"2024-12-20","current":-1.320411,"twenty":-3.487233,"median":-2.449166,"eighty":-1.053364,"marketCap":7221213},{"date":"2024-12-27","current":-1.354124,"twenty":-3.469339,"median":-2.436446,"eighty":-1.055406,"marketCap":7405585},{"date":"2025-01-03","current":-1.393455,"twenty":-3.460209,"median":-2.417636,"eighty":-1.071656,"marketCap":7620685},{"date":"2025-01-10","current":-1.18556,"twenty":-3.45108,"median":-2.415433,"eighty":-1.087177,"marketCap":6483728},{"date":"2025-01-17","current":-1.208035,"twenty":-3.441037,"median":-2.409546,"eighty":-1.102066,"marketCap":6606642},{"date":"2025-01-24","current":-1.112516,"twenty":-3.431907,"median":-2.407092,"eighty":-1.109145,"marketCap":6084256},{"date":"2025-01-31","current":-0.955191,"twenty":-3.419127,"median":-2.368422,"eighty":-1.085209,"marketCap":5223856},{"date":"2025-02-07","current":-1.039472,"twenty":-3.407716,"median":-2.352273,"eighty":-1.05223,"marketCap":5684785},{"date":"2025-02-14","current":-0.955191,"twenty":-3.391736,"median":-2.340001,"eighty":-1.033105,"marketCap":5223856},{"date":"2025-02-21","current":-0.915859,"twenty":-3.378041,"median":-2.326586,"eighty":-0.998824,"marketCap":5008756},{"date":"2025-02-28","current":-0.668633,"twenty":-3.378041,"median":-2.304429,"eighty":-0.984457,"marketCap":3656699},{"date":"2025-03-07","current":-0.406293,"twenty":-3.378041,"median":-2.256137,"eighty":-0.973171,"marketCap":2221982},{"date":"2025-03-14","current":-0.413918,"twenty":-3.37165,"median":-2.063455,"eighty":-0.968145,"marketCap":2263682},{"date":"2025-03-21","current":-0.675785,"twenty":-3.34426,"median":-1.851285,"eighty":-0.96081,"marketCap":3695808},{"date":"2025-03-28","current":-0.778466,"twenty":-3.336318,"median":-1.604046,"eighty":-0.955191,"marketCap":4257365},{"date":"2025-04-04","current":-0.500407,"twenty":-3.333578,"median":-1.540289,"eighty":-0.934537,"marketCap":3125408},{"date":"2025-04-11","current":-0.363417,"twenty":-3.331022,"median":-1.490993,"eighty":-0.836712,"marketCap":2269810},{"date":"2025-04-17","current":-0.292093,"twenty":-3.323718,"median":-1.4582,"eighty":-0.778466,"marketCap":1824333},{"date":"2025-04-25","current":-0.251335,"twenty":-3.263918,"median":-1.443055,"eighty":-0.679871,"marketCap":1569775},{"date":"2025-05-02","current":-0.270582,"twenty":-3.218269,"median":-1.417569,"eighty":-0.675289,"marketCap":1689983},{"date":"2025-05-09","current":-0.266053,"twenty":-3.204574,"median":-1.39741,"eighty":-0.646723,"marketCap":1661699},{"date":"2025-05-16","current":-0.262826,"twenty":-3.194988,"median":-1.384287,"eighty":-0.595535,"marketCap":1697054},{"date":"2025-05-23","current":-0.3205,"twenty":-3.194531,"median":-1.364277,"eighty":-0.557113,"marketCap":2069451},{"date":"2025-05-30","current":-0.451578,"twenty":-3.184305,"median":-1.354754,"eighty":-0.542732,"marketCap":2915816},{"date":"2025-06-06","current":-0.457969,"twenty":-3.174445,"median":-1.33918,"eighty":-0.520246,"marketCap":2957077},{"date":"2025-06-13","current":-0.462229,"twenty":-3.158012,"median":-1.322196,"eighty":-0.515702,"marketCap":2984585}],"updateTime":1750072522295}}}